4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

3 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

Wolfe Research initiated coverage of Alto Neuroscience with a rating of Outperform

BofA Securities initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $35.00

Chardan Capital Markets resumed coverage of Alto Neuroscience with a rating of Buy and set a new price target of $30.00

BTIG Research initiated coverage of Alto Neuroscience with a rating of Buy

Chardan Capital Markets initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $15.00

Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

William Blair initiated coverage of Alto Neuroscience with a rating of Outperform

TD Cowen initiated coverage of Alto Neuroscience with a rating of Outperform

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. "We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company," said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. "Few leaders in our industry have done more to a

Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&S alumni who are making transformational contributions to biomedical research within 25 years of graduation. "Having led global neuroscience R&D efforts for many years, I recognize that true transformation requires moving beyond the 'one-size-fits-all' model," said Husseini Manji, M.D., member of t

– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on EEG markers of general cognition as well as a test of attention – – Closed $120 million PIPE in March 2026; cash balance of approximately $264 million expected to fund planned operations through 2029, including a potential NDA submission for ALTO-207 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipe

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: Bank of America Securities Healthcare Conference, May 12-14, 2026 Format: Company presentation and one-on-one meetings Presentation Date & Time: May 13, 2026, 5:15 pm PDT Location: Las Vegas, NV Jefferies Global Healthcare Conference, June 2-4, 2026 Format: Fireside chat and one-on-one investor meetings Presentation Date & Time: June 3, 2026, 9:20 am EDT Location: Ne

— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7 million patient treatment-resistant depression market — — Phase 2b Ongoing with topline data expected in 2H 2027 — Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 (formerly CTC-501) in patients with Major Depressive Disorder (MDD). The data were presented in a poster session at t

— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial design and MADRS primary endpoint aligned with FDA standards in depression, potentially supporting a single Phase 3 registrational pathway — — Prior Phase 2a demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability — — Topline data expected in 2H 2027 — Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatmen

— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) — — Alto has developed a modified-release, once-daily oral formulation of ALTO-101; the Company plans to explore partnering opportunities for this formulation — — Development of ALTO-207 remains the top priority for the Company; Phase 2b on track to initiate in 1H 2026 — Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinic

– Financing led by Commodore Capital with participation from new and existing biotech focused investors – –  Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment Resistant Depression through a planned Phase 3 study and to a potential NDA submission – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately

– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – – External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments – – ALTO-101 granted FDA Fast Track Designation for CIAS; Topline Phase 2 Proof-of Concept data expected around the end of 1Q 2026 – – Year-end cash balance of $177 million expected to fund planned operations into 2028, covering four key data readouts across Alto's precision psychiatry pip

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto's website and a replay will be available following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobi

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

10-Q - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

EFFECT - Alto Neuroscience, Inc. (0001999480) (Filer)

S-3 - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

Miller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. "We are thrilled to welcome Andrew to Alto's Board at a transformative time for the Company," said Amit Etkin, M.D., Ph.D., Founder and Chief Executive Officer of Alto Neuroscience. "Few leaders in our industry have done more to a

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

– Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

– Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies. "Maha joins our Board at a pivotal moment for Alto, as we continu

– Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study expected to initiate by mid-2026 – – Topline data expected from Phase 2 proof-of-concept (POC) trial of ALTO-101 in schizophrenia in the second half of 2025; Phase 2b topline data readouts include ALTO-300 in MDD expected mid-2026 followed by ALTO-100 in bipolar depression expected in the sec

–  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design